Patents by Inventor Romy REIMANN

Romy REIMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs comprising an aminoalkyl glycine linker
    Patent number: 11633487
    Abstract: The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising these prodrugs and the use of these prodrugs. A disclosed prodrug may include a biologically active moiety reversibly and covalently linked to a specialized protective group; the linker may be reversible (i.e., hydrolytically cleavable in the absence of enzymes under physiological conditions) and, upon cleavage, may release a drug in its unmodified, pharmacologically active form.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: April 25, 2023
    Assignee: ASCENDIS PHARMA A/S
    Inventors: Nicola Bisek, Harald Rau, Felix Cleemann, Thomas Knappe, Romy Reimann
  • VEGF neutralizing prodrugs for the treatment of ocular conditions
    Patent number: 10519226
    Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: December 31, 2019
    Assignee: Ascendis Pharma Opthalmology Division A/S
    Inventors: Harald Rau, Thomas Knappe, Burkhardt Laufer, Romy Reimann, Samuel Weisbrod, Kennett Sprogøe, Nicola Bisek, Sebastian Stark, Tobias Voigt
  • Protecting Group Comprising a Purification Tag
    Publication number: 20180312582
    Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
    Type: Application
    Filed: July 3, 2018
    Publication date: November 1, 2018
    Applicant: Ascendis Pharma A/S
    Inventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
  • Protecting group comprising a purification tag
    Patent number: 10040850
    Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: August 7, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
  • Prodrugs Comprising an Aminoalkyl Glycine Linker
    Publication number: 20170224829
    Abstract: The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of said prodrugs.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 10, 2017
    Applicant: Ascendis Pharma A/S
    Inventors: Nicola BISEK, Harald RAU, Felix CLEEMANN, Thomas KNAPPE, Romy REIMANN
  • PROTECTING GROUP COMPRISING A PURIFICATION TAG
    Publication number: 20160257739
    Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
    Type: Application
    Filed: October 7, 2014
    Publication date: September 8, 2016
    Applicant: Ascendis Pharma A/S
    Inventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
  • Modified Hydrogels
    Publication number: 20160089446
    Abstract: The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the present invention. The hydrogel prodrug carrier has a reduced drug loading on the outside of the hydrogel carrier. This is achieved by reducing the number of functional groups of the hydrogel, in particular those at its surface.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 31, 2016
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich HERSEL, Harald RAU, Burkhardt LAUFER, Joachim ZETTLER, Romy REIMANN
  • VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions
    Publication number: 20150297740
    Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
    Type: Application
    Filed: October 8, 2013
    Publication date: October 22, 2015
    Inventors: Harald RAU, Thomas KNAPPE, Burkhardt Laufer, Romy REIMANN, Samuel WEISBROD, Kennett SPROGØE, Nicola BISEK, Sebastian STARK, Tobias VOIGT